重大事件
外國發行人報告
6-K
2026-07-02
Haleon財務總監獲績效股歸屬 出售部分股份支付稅務
AI 繁中摘要
Haleon plc（LSE/NYSE: HLN）提交6-K表格，披露一項董事/PDMR股權變動。事件涉及首席財務官Dawn Allen於2026年6月30日獲得2024年10月授予的績效股獎勵歸屬，該獎勵基於截至2025年12月31日的績效條件達成（詳見2025年報及20-F）。歸屬後隨即自動出售部分股份以支付稅務負債。
關鍵數字：歸屬股份283,193股（零成本），出售133,300股，每股售價£3.5239（倫敦證券交易所）。出售後Dawn Allen需按規定持有餘下股份直至滿足持股要求，且執行董事須持有至少兩年。該獎勵設有追回及沒收條款。
此申報屬常規股權激勵操作，反映管理層與股東利益一致，對投資者影響中性偏正面，顯示公司績效條件已達標，管理層持續專注長期價值。Haleon為專注日常健康的消費品公司，旗下品牌包括Advil、Centrum、Sensodyne等。
展開英文正文
6-K
1
a8474k.htm
DIRECTOR/PDMR SHAREHOLDING
a8474k
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2026
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Form
20-F ☒
Form
40-F ☐
EXHIBIT INDEX
Exhibit Number
Description
99.1
02 July
2026 - “Director/PDMR
Shareholding”
99.1
Haleon plc: Director/PDMR
Shareholding
2 July 2026: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces
notification and public disclosure in accordance with the
requirements of The UK Market Abuse Regulation of Transactions by a
Person Discharging Managerial Responsibilities
("PDMR").
This notification sets out the details of the vesting of a Haleon
share award over ordinary shares made to a PDMR in October 2024
under the Haleon Performance Share Plan and the subsequent sale of
ordinary shares to meet tax liabilities.
On 30 June 2026, Dawn Allen, Chief Financial Officer, received the
vesting of an award of Haleon ordinary shares under the Haleon
Performance Share Plan. Vesting included dividends
accrued.
The award under the Performance Share Plan was conditional on
continued employment and on the satisfaction of the performance
conditions over the performance period ended on 31 December 2025
approved by the Remuneration Committee, which (after tax on the
gross award) must be retained until the shareholding requirement is
met, and in any event for Executive Directors two years after
receipt.
Performance targets and levels of achievement are disclosed in the
2025 Annual Report and 20-F. The award is subject to malus and clawback
provisions.
1
Details of the issuer or emission allowance market
participant
a)
Name of the entity
Haleon plc
b)
LEI
549300PSB3WWEODCUP19
2
Reason for the notification
a)
Position/status
Chief Financial Officer
b)
Initial notification /Amendment to prior
notifications
Initial Notification
3
Details of the person discharging managerial responsibilities /
person closely associated ("PCA")
a)
PDMR/PCA
PDMR
b)
Name
Dawn Allen
4
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
a)
Description of Instrument
Share
Identification code
GB00BMX86B70
b)
Nature of the transaction
Acquisition of Ordinary Shares in respect of the Haleon plc
Performance Share Plan (Buyout award).
c)
Currency, Price(s) and Volume(s)
Price(s)
Volume(s)
Nil
283,193.151771
d)
Aggregated information
- Aggregated volume
N/A
- Price
e)
Date of the transaction
30 June 2026
f)
Place of the transaction
Outside a trading venue
4
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
a)
Description of Instrument
Share
Identification code
GB00BMX86B70
b)
Nature of the transaction
Automatic disposal of Ordinary Shares resulting from Haleon plc
Performance Share Plan (Buyout Award) vesting to cover tax
liabilities.
c)
Currency, Price(s) and Volume(s)
Price(s)
Volume(s)
£3.523867
133,300.732432
d)
Aggregated information
- Aggregated volume
N/A
- Price
e)
Date of the transaction
30 June 2026
f)
Place of the transaction
London Stock Exchange (XLON)
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused
on better everyday health. Our people, our brands, our research,
our investment and our innovation are aimed at improving the
everyday health of consumers. Our product portfolio spans six major
categories - Oral Health, Vitamins, Minerals and Supplements (VMS),
Pain Relief, Respiratory Health, Digestive Health and Therapeutic
Skin Health and Other. Our superior brands - such
as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion
consumers and are recommended by health professionals around the
world.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
HALEON PLC
(Registrant)
Date:
July 02, 2026
By:
/s/
Amanda Mellor
Name:
Amanda
Mellor
Title:
Company
Secretary